Immunovant, Inc.

Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage immunology company focused on developing FcRn inhibitor therapies for patients with immunoglobulin G-mediated autoimmune diseases. The company filed an 8-K current report with the SEC on August 13, 2024, under accession number 0001764013-24-000150, disclosing a material event as required under Exchange Act reporting obligations. Immunovant operates in the biopharmaceutical sector and has been publicly traded on Nasdaq, with its development pipeline centered on batoclimab, its lead anti-FcRn monoclonal antibody candidate. For comprehensive filing history, pipeline data, and real-time alerts on Immunovant and related biotech filings, sign up for full access at SpacDesk.